These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 32798495

  • 1. Sprifermin (recombinant human FGF18) is internalized through clathrin- and dynamin-independent pathways and degraded in primary chondrocytes.
    Sieber S, Gigout A.
    Exp Cell Res; 2020 Oct 15; 395(2):112236. PubMed ID: 32798495
    [Abstract] [Full Text] [Related]

  • 2. Sprifermin (rhFGF18) versus vehicle induces a biphasic process of extracellular matrix remodeling in human knee OA articular cartilage ex vivo.
    Reker D, Siebuhr AS, Thudium CS, Gantzel T, Ladel C, Michaelis M, Aspberg A, Berchtold MW, Karsdal MA, Gigout A, Bay-Jensen AC.
    Sci Rep; 2020 Apr 07; 10(1):6011. PubMed ID: 32265494
    [Abstract] [Full Text] [Related]

  • 3. Sprifermin (rhFGF18) enables proliferation of chondrocytes producing a hyaline cartilage matrix.
    Gigout A, Guehring H, Froemel D, Meurer A, Ladel C, Reker D, Bay-Jensen AC, Karsdal MA, Lindemann S.
    Osteoarthritis Cartilage; 2017 Nov 07; 25(11):1858-1867. PubMed ID: 28823647
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Sprifermin: a recombinant human fibroblast growth factor 18 for the treatment of knee osteoarthritis.
    Li J, Wang X, Ruan G, Zhu Z, Ding C.
    Expert Opin Investig Drugs; 2021 Sep 07; 30(9):923-930. PubMed ID: 34427483
    [Abstract] [Full Text] [Related]

  • 6. Sprifermin (rhFGF18) modulates extracellular matrix turnover in cartilage explants ex vivo.
    Reker D, Kjelgaard-Petersen CF, Siebuhr AS, Michaelis M, Gigout A, Karsdal MA, Ladel C, Bay-Jensen AC.
    J Transl Med; 2017 Dec 12; 15(1):250. PubMed ID: 29233174
    [Abstract] [Full Text] [Related]

  • 7. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors.
    Ellsworth JL, Berry J, Bukowski T, Claus J, Feldhaus A, Holderman S, Holdren MS, Lum KD, Moore EE, Raymond F, Ren H, Shea P, Sprecher C, Storey H, Thompson DL, Waggie K, Yao L, Fernandes RJ, Eyre DR, Hughes SD.
    Osteoarthritis Cartilage; 2002 Apr 12; 10(4):308-20. PubMed ID: 11950254
    [Abstract] [Full Text] [Related]

  • 8. Sprifermin treatment enhances cartilage integration in an in vitro repair model.
    Sennett ML, Meloni GR, Farran AJE, Guehring H, Mauck RL, Dodge GR.
    J Orthop Res; 2018 Oct 12; 36(10):2648-2656. PubMed ID: 29761549
    [Abstract] [Full Text] [Related]

  • 9. Identification of fibroblast growth factor-18 as a molecule to protect adult articular cartilage by gene expression profiling.
    Mori Y, Saito T, Chang SH, Kobayashi H, Ladel CH, Guehring H, Chung UI, Kawaguchi H.
    J Biol Chem; 2014 Apr 04; 289(14):10192-200. PubMed ID: 24577103
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sequential exposure to fibroblast growth factors (FGF) 2, 9 and 18 enhances hMSC chondrogenic differentiation.
    Correa D, Somoza RA, Lin P, Greenberg S, Rom E, Duesler L, Welter JF, Yayon A, Caplan AI.
    Osteoarthritis Cartilage; 2015 Mar 04; 23(3):443-53. PubMed ID: 25464167
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Recombinant human FGF18 preserves depth-dependent mechanical inhomogeneity in articular cartilage.
    Meloni GR, Farran A, Mohanraj B, Guehring H, Cocca R, Rabut E, Mauck RL, Dodge GR.
    Eur Cell Mater; 2019 Aug 08; 38():23-34. PubMed ID: 31393594
    [Abstract] [Full Text] [Related]

  • 16. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial.
    Lohmander LS, Hellot S, Dreher D, Krantz EF, Kruger DS, Guermazi A, Eckstein F.
    Arthritis Rheumatol; 2014 Jul 08; 66(7):1820-31. PubMed ID: 24740822
    [Abstract] [Full Text] [Related]

  • 17. Fibroblast Growth Factor Receptor 3 Inhibits Osteoarthritis Progression in the Knee Joints of Adult Mice.
    Tang J, Su N, Zhou S, Xie Y, Huang J, Wen X, Wang Z, Wang Q, Xu W, Du X, Chen H, Chen L.
    Arthritis Rheumatol; 2016 Oct 08; 68(10):2432-43. PubMed ID: 27159076
    [Abstract] [Full Text] [Related]

  • 18. Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial.
    Eckstein F, Kraines JL, Aydemir A, Wirth W, Maschek S, Hochberg MC.
    Ann Rheum Dis; 2020 Apr 08; 79(4):525-528. PubMed ID: 32098758
    [Abstract] [Full Text] [Related]

  • 19. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis.
    Davidson D, Blanc A, Filion D, Wang H, Plut P, Pfeffer G, Buschmann MD, Henderson JE.
    J Biol Chem; 2005 May 27; 280(21):20509-15. PubMed ID: 15781473
    [Abstract] [Full Text] [Related]

  • 20. Low levels of type II collagen formation (PRO-C2) are associated with response to sprifermin: a pre-defined, exploratory biomarker analysis from the FORWARD study.
    Bay-Jensen AC, Manginelli AA, Karsdal M, Luo Y, He Y, Michaelis M, Guehring H, Ladel C.
    Osteoarthritis Cartilage; 2022 Jan 27; 30(1):92-99. PubMed ID: 34737064
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.